New insights on ocular surface disease in patients with atopic dermatitis treated with dupilumab.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 34431510.
- Also identified by DOI 10.1111/bjd.20706.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Our study sought to describe ocular surface alterations at baseline and after 4 months of dupilumab treatment in patients with severe AD. Our findings highlight that all 25 patients showed ocular surface alterations prior to dupilumab treatment. Dupilumab may cause the worsening of clinical or subclinical pre-existing ocular alterations belonging to the spectrum of AKC.
Medical subject headings
- Dermatitis, Atopic
- Eczema